These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38042335)

  • 41. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neck.
    van der Linden N; van Gils CW; Pescott CP; Buter J; Vergeer MR; Groot CA
    Eur Arch Otorhinolaryngol; 2015 Aug; 272(8):2007-16. PubMed ID: 24943191
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Application of Discrete-Event Simulation in Health Technology Assessment: A Cost-Effectiveness Analysis of Alzheimer's Disease Treatment Using Real-World Evidence in Thailand.
    Kongpakwattana K; Chaiyakunapruk N
    Value Health; 2020 Jun; 23(6):710-718. PubMed ID: 32540228
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The cost-effectiveness of domiciliary non-invasive ventilation in patients with end-stage chronic obstructive pulmonary disease: a systematic review and economic evaluation.
    Dretzke J; Blissett D; Dave C; Mukherjee R; Price M; Bayliss S; Wu X; Jordan R; Jowett S; Turner AM; Moore D
    Health Technol Assess; 2015 Oct; 19(81):1-246. PubMed ID: 26470875
    [TBL] [Abstract][Full Text] [Related]  

  • 45. External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting.
    Hoogendoorn M; Feenstra TL; Asukai Y; Briggs AH; Hansen RN; Leidl R; Risebrough N; Samyshkin Y; Wacker M; Rutten-van Mölken MP
    Value Health; 2017 Mar; 20(3):397-403. PubMed ID: 28292484
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Calculating an intervention's (cost-)effectiveness for the real-world target population: the potential of combining strengths of both RCTs and observational data.
    Neyt M; Cleemput I; Thiry N; De Laet C
    Health Policy; 2012 Jul; 106(2):207-10. PubMed ID: 22608108
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimizing chronic disease management mega-analysis: economic evaluation.
    Path-Theta Collaboration
    Ont Health Technol Assess Ser; 2013; 13(13):1-148. PubMed ID: 24228076
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Integrating real-world data in cost-effectiveness analysis of universal HLA-B*15:02 screening in Malaysia.
    Chong HY; Lim KS; Fong SL; Shabaruddin FH; Dahlui M; Mei Lai PS; Ng CC; Chaiyakunapruk N
    Br J Clin Pharmacol; 2023 Nov; 89(11):3340-3351. PubMed ID: 37294011
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods.
    Hernández Alava M; Wailoo A; Pudney S; Gray L; Manca A
    Health Technol Assess; 2020 Jun; 24(34):1-68. PubMed ID: 32613941
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of a Clinical Trial-Derived Survival Model in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Coquet J; Bievre N; Billaut V; Seneviratne M; Magnani CJ; Bozkurt S; Brooks JD; Hernandez-Boussard T
    JAMA Netw Open; 2021 Jan; 4(1):e2031730. PubMed ID: 33481032
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Laparoscopic surgery for inguinal hernia repair: systematic review of effectiveness and economic evaluation.
    McCormack K; Wake B; Perez J; Fraser C; Cook J; McIntosh E; Vale L; Grant A
    Health Technol Assess; 2005 Apr; 9(14):1-203, iii-iv. PubMed ID: 15842951
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-utility analyses of targeted immunomodulators in rheumatoid arthritis: systematic review.
    Sussman M; Tao C; Patel P; Tundia N; Clewell J; Menzin J
    J Med Econ; 2020 Jun; 23(6):610-623. PubMed ID: 31971039
    [No Abstract]   [Full Text] [Related]  

  • 53. Dynamic zero-COVID strategy in controlling COVID-19 in Shanghai, China: A cost-effectiveness analysis.
    Tan C; Luo X; Zhou Z; Zeng X; Wan X; Yi L; Liu Q
    J Infect Public Health; 2023 Jun; 16(6):893-900. PubMed ID: 37062164
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
    Armoiry X; Connock M; Tsertsvadze A; Cummins E; Melendez-Torres GJ; Royle P; Clarke A
    Pharmacoeconomics; 2018 Sep; 36(9):1073-1081. PubMed ID: 29582405
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Büyükkaramikli NC; de Groot S; Riemsma R; Fayter D; Armstrong N; Portegijs P; Duffy S; Kleijnen J; Al MJ
    Pharmacoeconomics; 2019 Feb; 37(2):141-153. PubMed ID: 30194622
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tranexamic acid in the routine treatment of postpartum hemorrhage in the United States: a cost-effectiveness analysis.
    Sudhof LS; Shainker SA; Einerson BD
    Am J Obstet Gynecol; 2019 Sep; 221(3):275.e1-275.e12. PubMed ID: 31226298
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis.
    Riemsma R; Al M; Corro Ramos I; Deshpande SN; Armstrong N; Lee YC; Ryder S; Noake C; Krol M; Oppe M; Kleijnen J; Severens H
    Health Technol Assess; 2013 Dec; 17(61):1-236. PubMed ID: 24351663
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rapid antigen detection and molecular tests for group A streptococcal infections for acute sore throat: systematic reviews and economic evaluation.
    Fraser H; Gallacher D; Achana F; Court R; Taylor-Phillips S; Nduka C; Stinton C; Willans R; Gill P; Mistry H
    Health Technol Assess; 2020 Jun; 24(31):1-232. PubMed ID: 32605705
    [TBL] [Abstract][Full Text] [Related]  

  • 59. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in France.
    de Pouvourville G; Blin P; Karam P
    Eur J Health Econ; 2020 Mar; 21(2):235-249. PubMed ID: 31650440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.